Categories
Gemopatrilat
Topic: Chemistry
From Handwiki - Reading time: 2 minShort description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | BMS-189921 |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C19H26N2O4S |
| Molar mass | 378.49 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Gemopatrilat (INN)[1] is an experimental drug that was never marketed.[2] It acts as a vasopeptidase inhibitor.[3][4] It inhibits both angiotensin-converting enzyme (ACE) and neutral endopeptidase (neprilysin).[5]
References
- ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 46". World Health Organization. p. 200. https://www.who.int/medicines/publications/druginformation/innlists/RL64.pdf.
- ↑ "Gemopatrilat". AdisInsight. http://adisinsight.springer.com/drugs/800009581. "Highest Development Phases: Discontinued"
- ↑ "Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes". Kidney International 63 (1): 64–71. January 2003. doi:10.1046/j.1523-1755.2003.00708.x. PMID 12472769. https://www.kidney-international.org/article/S0085-2538(15)48845-3/fulltext.
- ↑ "Metabolism of [14C]gemopatrilat after oral administration to rats, dogs, and humans". Drug Metabolism and Disposition 34 (6): 961–70. June 2006. doi:10.1124/dmd.105.007500. PMID 16540589.
- ↑ "In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat". Journal of Hypertension 19 (5): 941–6. May 2001. doi:10.1097/00004872-200105000-00015. PMID 11393678.
 |  |
This article is licensed under CC BY-SA 3.0.
Original source: https://handwiki.org/wiki/Gemopatrilat
Status: article is cached
Original source: https://handwiki.org/wiki/Gemopatrilat
Status: article is cached
EncycloReader
is supported by the 
KSF